Prostate Cancer Screening

Prostate cancer represents one of the most frequent cancers affecting men worldwide. Screening for prostate cancer remains an essential strategy in reducing mortality and morbidity and also in improving the quality of life of men affected by this pathology. On the other hand, there is a fine line between screening, diagnosis, and treatment of prostate cancer and overdiagnosis with unnecessary biopsies. In this direction, many strategies have been carried out, the first evaluation stratifying men into low-risk and high-risk for prostate cancer. Low-risk male patients should undergo an evaluation every eight years, while high-risk male patients are recommended to be evaluated every two years. The aim of this paper is to describe the target population for prostate cancer screening, as well as different methods of prostate cancer assessment and monitoring, in order to ensure the optimum healthcare for male patients.